Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation

NCT ID: NCT01223612

Last Updated: 2020-09-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2012-07-31

Brief Summary

This exploratory study will compare the effects of ranibizumab treatment with conventional macular laser therapy for patients with diabetic macular oedema.

The study hypothesises that treatment with ranibizumab may be superior to laser treatment in terms of improving vision and decreasing retinal thickness.

Patients will be randomised to receive either repeated injections of ranibizumab every 4 weeks for 48 weeks or macular laser therapy every 12 weeks for 48 weeks.

At baseline, and then at 12, 24 and 48 weeks, patients will undergo detailed testing to provide information on the structure and function of the retina with both of these treatments.

Detailed Description

Adult patients with centre-involving diabetic macular oedema will be recruited to this single-centre study. Patients will undergo detailed baseline evaluation which will include:

• vision testing
• optical coherence tomography scanning
• fundus fluorescein angiography
• microperimetry
• colour contrast sensitivity testing
• electrophysiological testing

Patients will be randomised 2:1 to receive either ranibizumab intravitreal injection 4-weekly for 48 weeks or modified ETDRS macular laser therapy 12-weekly for 48 weeks.

Both groups of patients will return at 12, 24 and 48 weeks for repeat testing of the parameters evaluated at baseline.

Conditions

Diabetic Retinopathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ranibizumab

Intravitreal injection of ranibizumab

Group Type: EXPERIMENTAL

Ranibizumab

Intervention Type: DRUG

Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.

Laser

Modified ETDRS laser

Group Type: ACTIVE_COMPARATOR

Modified ETDRS laser

Intervention Type: PROCEDURE

Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.

Interventions

Ranibizumab

Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.

Intervention Type: DRUG

Modified ETDRS laser

Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.

Intervention Type: PROCEDURE

Other Intervention Names

Lucentis; Argon laser photocoagulation

Eligibility Criteria

Inclusion Criteria

• Diagnosis of diabetes mellitus (type 1 or type 2)
• Retinal thickening due to diabetic macular oedema involving the centre of the macula and OCT central subfield ≥ 300 microns
• Best corrected visual acuity in the study eye between 55 and 79 ETDRS letters at 1 metre (Snellen equivalent ≥ 6/24 and ≤ 6/9)
• Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs
• Intraocular pressure less than 30 mmHg
• Ability to return for study visits
• Visual acuity in fellow eye ≥ 2/60
• Fellow eye has received no anti-VEGF treatment within the past 3 months and no expectation of such treatment in next 12 months
• No previous laser within 3 months of randomisation
• Ability to give informed consent throughout the duration of the study

Exclusion Criteria

• Macular ischaemia
• Macular oedema from a cause other than diabetic macular oedema
• Co-existent ocular disease
• Presence of an ocular condition such that visual acuity would not improve from resolution of macular oedema
• Presence of an ocular condition that might affect macular oedema or alter visual acuity during the course of the study
• A substantial cataract that is likely to be decreasing visual acuity by 3 lines or more
• History of treatment for diabetic macular oedema at any time in the past 3 months
• History of panretinal scatter photocoagulation (PRP) within 3 months prior to randomisation
• Anticipated need for PRP in the 6 months following randomisation.
• Proliferative diabetic retinopathy in the study eye.
• A condition that, in the opinion of the investigator, would preclude participation in the study.
• Haemoglobin A1c > 11.0 %
• A past medical history of significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant
• Blood pressure >170/100 mmHg
• Myocardial infarction, other cardiac event requiring hospitalisation, stroke, transient ischaemic attack, or treatment for acute congestive heart failure within 6 months prior to randomisation
• Major surgery within 28 days prior to randomisation or major surgery planned during the next 12 months at baseline
• Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug that has not received regulatory approval at the time of study entry. Note: subjects cannot receive another investigational drug while participating in the study
• Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomisation
• Pregnant or lactating women or women intending to become pregnant within the study period including 3 months after study cessation
• History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery) within prior 3 months or anticipated within the next 6 months following randomisation.
• Aphakia
• Uncontrolled glaucoma
• External ocular infection, including conjunctivitis, chalazion, or severe blepharitis
• Known allergy to fluorescein dye or to any component of the study drug
• Fertile male unwilling to use contraception for the duration of the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philip G Hykin, FRCS FRCOphth

Role: PRINCIPAL_INVESTIGATOR

Moorfields Eye Hospital NHS Trust

Locations

Moorfields Eye Hospital

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

HYKP1015

Identifier Type: -

Identifier Source: org_study_id